Bartłomiej Milanowski

Dr. Bartłomiej Milanowski

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2024 in Polymers
Verified
Journal Article
Open access
PDF file
HWHanna Wosicka-Frąckowiak
Hanna Wosicka-Frąckowiak
KPKornelia Poniedziałek
Kornelia Poniedziałek
SWStanisław Woźny
Stanisław Woźny
MKMateusz Kuprianowicz
Mateusz Kuprianowicz
MNMartyna Nyga
Martyna Nyga
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
Biomaterials have been the subject of extensive research, and their applications in medicine and pharmacy are expanding rapidly. Collagen and its derivatives stand out as valuable biomaterials due to their high biocompatibility, biodegradability, and lack of toxicity and immunogenicity. This review comprehensively examines collagen from various sources, its extraction and processing methods, and its structural and functional properties. Preserving the native state of collagen is crucial for maintaining its beneficial characteristics. The challenges associated with chemically modifying collagen to tailor its properties for specific clinical needs are also addressed. The review discusses various collagen-based biomaterials, including solutions, hydrogels, powders, sponges, scaffolds, and thin films. These materials have broad applications in regenerative medicine, tissue engineering, drug delivery, and wound healing. Additionally, the review highlights current research trends related to collagen and its derivatives. These trends may significantly influence future developments, such as using collagen-based bioinks for 3D bioprinting or exploring new collagen nanoparticle preparation methods and drug delivery systems.

18 December 2015 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
MTMichał Teżyk
Michał Teżyk
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
AEAndrzej Ernst
Andrzej Ernst
JLJanina Lulek
Janina Lulek
Context: Continuous processing is an innovative production concept well known and successfully used in other industries for many years. The modern pharmaceutical industry is facing the challenge of transition from a traditional manufacturing approach based on batch-wise production to a continuous manufacturing model.Objective: The aim of this article is to present technological progress in manufacturing based on continuous and semi-continuous processing of the solid oral dosage forms.Methods: Single unit processes which possess an alternative processing pathway to batch-wise technology or, with some modification, an altered approach that may run continuously, and are thus able to seamlessly switch to continuous manufacturing are briefly presented. Furthermore, the concept of semi-continuous processing is discussed. Subsequently more sophisticated production systems that were created by coupling single unit processes and comprise all the steps of production, from powder to final dosage form, were r...

16 January 2018 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
MRMarek Rychter
Marek Rychter
ABAnna Baranowska-Korczyc
Anna Baranowska-Korczyc
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
Marcin JarekMarcin Jarek
Marcin Jarek
BMBarbara M. Maciejewska
Barbara M. Maciejewska
JLJanina Lulek
Janina Lulek
The study discusses the value of electrospun cilostazol-loaded (CIL) polymer structures for potential vascular implant applications.

8 December 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Marcin SKOTNICKIMarcin SKOTNICKI
Marcin SKOTNICKI
DADavid C. Apperley
David C. Apperley
JAJuan A. Aguilar
Juan A. Aguilar
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
MPMarek Pyda
Marek Pyda
PHPaul Hodgkinson
Paul Hodgkinson

14 March 2022 in Materials
Verified
Journal Article
Open access
PDF file
Piotr KulinowskiPiotr Kulinowski
Piotr Kulinowski
PMPiotr Malczewski
Piotr Malczewski
MŁMarta Łaszcz
Marta Łaszcz
EBEwelina Baran
Ewelina Baran
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
Przemysław DorożyńskiPrzemysław Dorożyński
Przemysław Dorożyński
3D printing by selective laser sintering (SLS) of high-dose drug delivery systems using pure brittle crystalline active pharmaceutical ingredients (API) is possible but impractical. Currently used pharmaceutical grade excipients, including polymers, are primarily designed for powder compression, ensuring good mechanical properties. Using these excipients for SLS usually leads to poor mechanical properties of printed tablets (printlets). Composite printlets consisting of sintered carbon-stained polyamide (PA12) and metronidazole (Met) were manufactured by SLS to overcome the issue. The printlets were characterized using DSC and IR spectroscopy together with an assessment of mechanical properties. Functional properties of the printlets, i.e., drug release in USP3 and USP4 apparatus together with flotation assessment, were evaluated. The printlets contained 80 to 90% of Met (therapeutic dose ca. 600 mg), had hardness above 40 N (comparable with compressed tablets) and were of good quality with internal porous structure, which assured flotation. The thermal stability of the composite material and the identity of its constituents were confirmed. Elastic PA12 mesh maintained the shape and structure of the printlets during drug dissolution and flotation. Laser speed and the addition of an osmotic agent in low content influenced drug release virtually not changing composition of the printlet; time to release 80% of Met varied from 0.5 to 5 h. Composite printlets consisting of elastic insoluble PA12 mesh filled with high content of crystalline Met were manufactured by 3D SLS printing. Dissolution modification by the addition of an osmotic agent was demonstrated. The study shows the need to define the requirements for excipients dedicated to 3D printing and to search for appropriate materials for this purpose.

18 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marcin SKOTNICKIMarcin SKOTNICKI
Marcin SKOTNICKI
Barbara JadachBarbara Jadach
Barbara Jadach
ASAgnieszka Skotnicka
Agnieszka Skotnicka
Bartłomiej MilanowskiBartłomiej Milanowski
Bartłomiej Milanowski
Lidia TajberLidia Tajber
Lidia Tajber
Jacek KujawskiJacek Kujawski
Jacek Kujawski
The aim of this study was to characterize a 1:1 molar ratio of a pharmacologically relevant co-amorphous atorvastatin-irbesartan (ATR-IRB) system obtained by quench cooling of the crystalline ATR/IRB physical mixture for potential use in the fixed-dose combination therapy. The system was characterized by employing standard differential scanning calorimetry (DSC), Fourier transform-infrared spectroscopy (FT-IR), and intrinsic dissolution rate studies. Quantum mechanical calculations were performed to obtain information regarding intermolecular interactions in the studied co-amorphous ATR-IRB system. The co-amorphous formulation showed a significant improvement in the intrinsic dissolution rate (IDR) of IRB over pure crystalline as well as its amorphous counterpart. An unusual behavior was observed for ATR, as the IDR of ATR in the co-amorphous formulation was slightly lower than that of amorphous ATR alone. Short-term physical aging studies of up to 8 h proved that the ATR-IRB co-amorphous system remained in the amorphous form. Furthermore, no physical aging occurred in the co-amorphous system. FT-IR, density functional theory calculations, and analysis of Tg value of co-amorphous system using the Couchman–Karasz equation revealed the presence of molecular interactions between APIs, which may contribute to the increased physical stability.